[SUCCESSFUL TREATMENT FOR OTITIS MEDIA AND SINUSITIS ASSOCIATED WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS USING ANTI-IL-5 RECEPTOR MONOCLONAL ANTIBODY BENRALIZUMAB]

Arerugi. 2022;71(3):242-247. doi: 10.15036/arerugi.71.242.
[Article in Japanese]

Abstract

Eosinophilic granulomatosis with polyangiitis (EGPA) is a type of ANCA-related vasculitis. Asthma and sinusitis occur first in the course of EGPA, followed by vasculitis symptoms such as fever, weight loss, and peripheral neuropathy. Otitis media with effusion and sensorineural hearing loss occur occasionally in EGPA patients. Here we report a case of a 39-years-old female patient with asthma that developed at age 37 and sinusitis. The patient was diagnosed with EGPA and treatment was started with oral corticosteroids. During the course of treatment, otitis media with effusion and sensorineural hearing loss developed. Benralizumab was administered for severe asthma. After treatment with benralizumab, the symptoms of asthma, otitis media with effusion and sinusitis dramatically improved. This is the first reported case in which benralizumab was used for treating otitis media and sinusitis associated with EGPA. The findings suggest that benralizumab may be effective for otitis media and sinusitis associated with EGPA.

Keywords: benralizumab; chronic sinusitis; eosinophilic granulomatosis with polyangiitis; otitis media with effusion.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Asthma* / complications
  • Asthma* / drug therapy
  • Churg-Strauss Syndrome* / complications
  • Female
  • Granulomatosis with Polyangiitis* / complications
  • Granulomatosis with Polyangiitis* / diagnosis
  • Granulomatosis with Polyangiitis* / drug therapy
  • Hearing Loss, Sensorineural* / complications
  • Humans
  • Otitis Media with Effusion* / complications
  • Otitis Media with Effusion* / drug therapy
  • Otitis Media* / complications
  • Receptors, Interleukin-5
  • Sinusitis* / complications
  • Sinusitis* / drug therapy

Substances

  • Antibodies, Monoclonal, Humanized
  • Receptors, Interleukin-5
  • benralizumab